Verona Pharma plc – NASDAQ:VRNA
Verona Pharma stock price today
$105.32
+59.12
+128.01%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Verona Pharma stock price monthly change
+121.85%
month
Verona Pharma stock price quarterly change
+121.85%
quarter
Verona Pharma stock price yearly change
+125.65%
year
Verona Pharma key metrics
Market Cap | 3.53B |
Enterprise value | 1.03B |
P/E | -20.87 |
EV/Sales | 2.25 |
EV/EBITDA | -0.01 |
Price/Sales | 2.74 |
Price/Book | 5.46 |
PEG ratio | N/A |
EPS | -0.78 |
Revenue | N/A |
EBITDA | -69.04M |
Income | -63.52M |
Revenue Q/Q | N/A |
Revenue Y/Y | 105.25% |
Profit margin | -15000.22% |
Oper. margin | -16539.3% |
Gross margin | 24.45% |
EBIT margin | -16539.3% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVerona Pharma stock price history
Verona Pharma stock forecast
Verona Pharma financial statements
Average Price Target
$42
Potential downside: -60.12%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -8.80M | |
|---|---|---|---|
| Sep 2023 | 0 | -14.68M | |
| Dec 2023 | 940.05K | -14.25M | -1516.39% |
| Mar 2024 | 0 | -25.77M |
| 2024-02-29 | -0.23 | -0.16 |
|---|---|---|
| 2024-05-09 | -0.24 | -0.32 |
| Jun 2023 | 303929000 | 30.83M | 10.15% |
|---|---|---|---|
| Sep 2023 | 292470000 | 28.93M | 9.89% |
| Dec 2023 | 308124000 | 58.84M | 19.1% |
| Mar 2024 | 289912000 | 64.92M | 22.39% |
| Jun 2023 | -21.31M | 0 | 124K |
|---|---|---|---|
| Sep 2023 | -12.72M | 0 | 48K |
| Dec 2023 | -10.42M | -37.06K | 24.06M |
| Mar 2024 | -13.96M | -15.99K | -2.75M |
Verona Pharma alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 79 |
| Apr 2024 | 79 |
| May 2024 | 79 |
| Jun 2024 | 79 |
| Jul 2024 | 79 |
Verona Pharma other data
3.83%
-6.18%
of VRNA is owned by hedge funds
46
-40
20.26M
-34.18M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 36248 |
| May 2024 | 0 | 36248 |
| Aug 2024 | 36000 | 800000 |
| Sep 2024 | 0 | 1200000 |
| Oct 2024 | 0 | 1329296 |
| Nov 2024 | 101240 | 753272 |
| Dec 2024 | 0 | 1757432 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ZACCARDELLI DAVID director, officer.. | Ordinary Shares | 162,800 | $5.01 | $815,465 | ||
Sale | HAHN MARK W officer: Chief Fi.. | Ordinary Shares | 183,728 | $5.01 | $920,294 | ||
Sale | ZACCARDELLI DAVID director, officer.. | Ordinary Shares | 640,264 | $5.01 | $3,205,162 | ||
Sale | HAHN MARK W officer: Chief Fi.. | Ordinary Shares | 640,048 | $5.01 | $3,204,080 | ||
Sale | ZACCARDELLI DAVID director, officer.. | Ordinary Shares | 67,608 | $5 | $338,175 | ||
Sale | HAHN MARK W officer: Chief Fi.. | Ordinary Shares | 58,184 | $5 | $290,978 | ||
Sale | HAHN MARK W officer: Chief Fi.. | Ordinary Shares | 1,600 | $5 | $8,000 | ||
Sale | ZACCARDELLI DAVID director, officer.. | Ordinary Shares | 3,200 | $5 | $16,000 | ||
Sale | HAHN MARK W officer: Chief Fi.. | Ordinary Shares | 98,704 | $5.01 | $494,112 | ||
Sale | ZACCARDELLI DAVID director, officer.. | Ordinary Shares | 98,888 | $5.01 | $495,033 |
| Patent |
|---|
Application Filling date: 12 Aug 2020 Issue date: 25 Aug 2022 |
Application Filling date: 9 Oct 2019 Issue date: 9 Dec 2021 |
Application Filling date: 16 Nov 2020 Issue date: 15 Apr 2021 |
Grant Filling date: 21 Mar 2018 Issue date: 16 Mar 2021 |
Grant Utility: Treatment Filling date: 11 May 2015 Issue date: 15 Dec 2020 |
Grant Utility: Compound and process Filling date: 27 Jul 2017 Issue date: 14 Jul 2020 |
Application Filling date: 24 Sep 2019 Issue date: 16 Jan 2020 |
Grant Filling date: 5 Jun 2017 Issue date: 12 Nov 2019 |
Grant Filling date: 10 Feb 2016 Issue date: 5 Nov 2019 |
Application Filling date: 27 Jul 2017 Issue date: 31 Oct 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
Itepekimab Failure A Setback For Sanofi And Regeneron
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon
Verona Pharma: Financial Health And COPD Market Impact 2024
-
What's the price of Verona Pharma stock today?
One share of Verona Pharma stock can currently be purchased for approximately $105.32.
-
When is Verona Pharma's next earnings date?
Unfortunately, Verona Pharma's (VRNA) next earnings date is currently unknown.
-
Does Verona Pharma pay dividends?
No, Verona Pharma does not pay dividends.
-
How much money does Verona Pharma make?
Verona Pharma has a market capitalization of 3.53B. Verona Pharma made a loss 54.37M US dollars in net income (profit) last year or -$0.32 on an earnings per share basis.
-
What is Verona Pharma's stock symbol?
Verona Pharma plc is traded on the NASDAQ under the ticker symbol "VRNA".
-
What is Verona Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Verona Pharma?
Shares of Verona Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the following people:
- Dr. Kathleen A. Rickard Chief Medical Officer(age: 67, pay: $722,760)
- Dr. David S. Zaccardelli Pres, Chief Executive Officer & Executive Director(age: 60, pay: $701,630)
- Mr. Mark W. Hahn Chief Financial Officer(age: 62, pay: $560,070)
-
How many employees does Verona Pharma have?
As Jul 2024, Verona Pharma employs 79 workers.
-
When Verona Pharma went public?
Verona Pharma plc is publicly traded company for more then 8 years since IPO on 28 Apr 2017.
-
What is Verona Pharma's official website?
The official website for Verona Pharma is veronapharma.com.
-
How can i contact Verona Pharma?
Verona Pharma can be reached via phone at +44 20 3283 4200.
-
What is Verona Pharma stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Verona Pharma in the last 12 months, the avarage price target is $42. The average price target represents a -60.12% change from the last price of $105.32.
Verona Pharma company profile:
Verona Pharma plc
veronapharma.comExchange:
NASDAQ
Full time employees:
79
Industry:
Biotechnology
Sector:
Healthcare
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
3 More London Riverside
London, SE1 2RE
London, SE1 2RE
CIK: 0001657312
ISIN: US9250501064
CUSIP: 925050106
